Table 2.
Targets | Agents | Mechanisms | Developments |
---|---|---|---|
CPT1A | Etomoxir | Inhibition of FAO | Preclinical |
CTLA‐4 | Ipilimumab | Checkpoint blockade; inhibition of FAO | FDA‐Approved |
PD‐1/PD‐L1 | Nivolumab, Pembrolizumab, Atezolizumab 2 | Checkpoint blockade; inhibition of FAO | FDA‐Approved |
AMPK | Metformin | Increased FAO | FDA‐Approved |
Abbreviations: AMPK, adenosine monophosphate‐activated kinase; CPT1A, carnitine palmitoyltransferase 1‐a; CTLA‐4, cytotoxic T lymphocyte antigen 4; FAO, fatty acid β‐oxidation; PD‐1, programmed cell death‐1.